Cabibbo Giuseppe, Tremosini Silvia, Galati Giovanni, Mazza Giancarlo, Gadaleta-Caldarola Gennaro, Lombardi Giuseppe, Antonucci Michela, Sacco Rodolfo
Section of Gastroenterology, DIBIMIS, University of Palermo, 90127 Palermo, Italy.
Expert Rev Anticancer Ther. 2014 Jul;14(7):831-45. doi: 10.1586/14737140.2014.920694. Epub 2014 May 22.
Transarterial chemoembolization (TACE) is considered as the standard therapy for patients with intermediate-stage hepatocellular carcinoma. However, given the high heterogeneity of this population, no common strategy or protocol standardization has been defined yet. In the last few years TACE treatment has been combined with sorafenib systemic therapy, reporting overall positive results both in terms of safety and efficacy. This systematic review presents and critically discusses the evidence available on the use of TACE in combination (concomitant or sequential) with sorafenib, focusing also on clinical trials currently ongoing to better define an optimal therapeutic strategy for this group of patients.
经动脉化疗栓塞术（TACE）被认为是中期肝细胞癌患者的标准治疗方法。然而，鉴于该人群的高度异质性，尚未确定通用的策略或方案标准化。在过去几年中，TACE治疗已与索拉非尼全身治疗相结合，在安全性和有效性方面均报告了总体积极结果。本系统评价展示并批判性地讨论了有关TACE与索拉非尼联合使用（同时或序贯）的现有证据，同时也关注目前正在进行的临床试验，以更好地确定针对这组患者的最佳治疗策略。
